Effects of de-escalated bisphosphonate therapy on the Functional Assessment of Cancer Therapy-Bone Pain, Brief Pain Inventory and bone biomarkers  by Kuchuk, Iryna et al.
Research Article
Effects of de-escalated bisphosphonate therapy on the Functional
Assessment of Cancer Therapy-Bone Pain, Brief Pain Inventory and
bone biomarkers
Iryna Kuchuk a, Jennifer L. Beaumont b, Mark Clemons a,c, Eitan Amir d,
Christina L. Addison a,c, David Cella b,n
a Division of Medical Oncology, Ottawa Regional Cancer Centre and University of Ottawa, Ottawa, Canada
b Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, USA
c Ottawa Hospital Research Institute, Ottawa, Canada
d Division of Hematology and Oncology, The Princess Margaret Hospital, University of Toronto, Toronto, Canada
a r t i c l e i n f o
Article history:
Received 6 May 2013
Received in revised form
26 July 2013
Accepted 31 July 2013








a b s t r a c t
Background: The Brief Pain Inventory (BPI) and Functional Assessment of Cancer Therapy-Bone Pain
(FACT-BP) are commonly used measures of patient reported pain outcomes. We report on the
performance of the FACT-BP in comparison to the BPI within a small, randomized trial.
Methods: Patients with biochemically deﬁned low risk bone metastases were randomized to 4 weekly
(control arm) or 12 weekly (de-escalating arm) pamidronate for 1 year. FACT-BP, BPI and serum markers
of bone turnover were recorded at baseline and weeks 12, 24, 36 and 48. Mixed effects models were used
to compare scores over time between arms. Correlation coefﬁcients were calculated to evaluate the
association between FACT-BP and BPI scores, as well as with markers of bone turnover.
Results: Nineteen patients were randomized to each study arm. Pain scores determined by the two
instruments were moderately to highly correlated with each other. Baseline C-telopeptide (CTx) level
was correlated with baseline FACT-BP and BPI scores. Baseline bone-speciﬁc alkaline phosphatase
showed a non-signiﬁcant association with pain scores. There were no correlations between the markers
of bone turnover and pain scores at week 12.
Conclusions: In the current study the FACT-BP and BPI correlated well with each other, and with baseline
CTx. The possibility of linking subjective pain scores with objective biomarkers of response requires more
investigation.
& 2013 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Bone pain is a common symptom in patients with metastatic
disease and can be severe, debilitating, and signiﬁcantly interfere
with a patient's quality of life. It is therefore important to develop
validated measures of patient-reported outcomes such as, bone pain,
impact on daily activities, and quality of life (QoL) to evaluate the
efﬁcacy of both anti-cancer drugs and bone-targeted agents [1].
The method of obtaining these measures also needs to be practical to
allow for routine use in the clinic [2,3].
One of the most commonly used tools to assess pain is the Brief
Pain Inventory (BPI) that was developed by the Pain Research Group
of the WHO Collaborating Center for Symptom Evaluation in Cancer
Care. BPI consists of 11 questions designed to assess pain location,
severity, relief and interference [4]. The Functional Assessment of
Cancer Therapy-Bone Pain (FACT-BP) [5] was developed to speciﬁ-
cally assess cancer-related bone pain and its effects on patient QoL.
The FACT-BP is a 16-item scale. Fifteen of the items are used to
calculate a summed score, with higher aggregate scores representing
less bone pain, or better QoL. After its initial launch, the question-
naire was subsequently modiﬁed and currently two versions exist:
the 16-item version and a 20-item version that includes minor
rewording of ﬁve items and a more detailed assessment of the
impact of pain on daily functioning [6] (Table 1).
The 16-item version was evaluated in two prospective phase II
trials of similar design in which less potent bisphosphonates were
switched to a third-generation bisphosphonate (zoledronic acid in
one and ibandronate in other study) [5]. FACT-BP has been shown to
be a robust and concise tool for assessing cancer-related bone pain
in addition to the impact of that pain upon functioning and QoL [5].
We have recently completed a prospective randomized feasi-
bility study of de-escalated bisphosphonate treatment with
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intravenous pamidronate in patients with metastatic breast cancer
to bone [7]. Here we report on an analysis utilizing data from this
trial aimed at comparing BPI and FACT-BP and to correlate these
with bone turnover markers.
2. Methods
We utilized data from a randomized, non-inferiority feasibility
trial conducted in a single large cancer center [7]. The trial
enrolled women with breast cancer and radiological or biopsy
conﬁrmed bone metastases with bone turnover marker C-
telopeptide (CTx) levels in the low-risk range (deﬁned as serum
CTx levels in the lowest tertile [o600 ng/L]). Eligible patients
were stratiﬁed according to baseline serum CTx (o400 ng/L and
400–600 ng/L) and duration of prior bisphosphonate use (o6
months and 46 months) and were then randomly allocated to
receive 90 mg pamidronate intravenously every 3–4 weeks (con-
trol group) or every 12 weeks (de-escalated group). Serum was
collected from enrolled patients following an overnight fast at
baseline and weeks 12, 24, 36 and 48. Patients also completed the
BPI and the 16-item version of FACT-BP at the same times at
baseline, and weeks 12, 24, 36 and 48. Those remaining in the low-
risk CTx group continued to receive their allocated treatment.
Those whose CTx levels rose above 600 ng/L remained on study,
but thereafter received treatment every 3–4 weeks. Censoring was
carried out for any patient receiving radiation therapy to bone or a
change in systemic therapy. The trial was approved by the
respective institutional Research Ethic Board.
Data on cumulative scores for both BPI and FACT-BP have been
reported elsewhere [7]. Here, we also assessed item-level scores
such as average pain over the past 7 days, worst pain over the past
7 days, and pain right now.
2.1. Bone turnover marker analysis
At baseline and various times on treatment, serum samples were
obtained and analyzed for levels of the bone turnover markers CTx
and BSAP using speciﬁc enzyme linked immunosorbent assay
(ELISA). The threshold of sensitivity for CTx was 10 ng/L (Beta-
Cross Laps/Serum Assay, Roche Diagnostics Canada Inc.), while it was
0.7 IU/L for BSAP (Metra Biosystems, San Diego CA).
2.2. Statistical analysis
A mixed effects model for repeated measures was used to
compare scores over time between treatment arms. An unstruc-
tured covariance pattern was used to account for the correlations
within patients. The model included ﬁxed effects (treatment arm,
time [measured in weeks], and a treatment time interaction
term) and random effects (patient, patient time). Pearson corre-
lation coefﬁcients were calculated to evaluate the association
between FACT-BP and BPI scores, along with the association of
FACT-BP and BPI scores with levels of bone turnover markers at
baseline and week 12 time points.
3. Results
A total of 38 patients were randomized with 19 patients in each
arm, and 29 patients completed FACT-BP and BPI at baseline.
At week 12, data was available for correlation of pain scores with
bone turnover marker levels for 22 patients, 11 patients completed
questionnaires at week 48 (Table 2).
3.1. Correlation between BPI and FACT-BP
Results of the FACT-BP scores at each time point for patients in
the study are plotted by treatment arm in Fig. 1. Using a mixed
effects model, the trend in pain scores over time did not sig-
niﬁcantly differ between groups (p¼0.386). Similarly, there were
no differences in trends between treatment arms in the BPI ratings
of average pain (p¼0.164), worst pain (p¼0.297), and pain right
Table 1
Items included in the 16- and 20-item versions of the FACT-BP.
16-item version [6,9] 20-item version [10]
GF7 I am content with the quality of my life right now X X
P2 I have certain parts of my body where I experience osigniﬁcant4 pain X X
BP1 I have bone pain X X
BP2 It hurts when I put weight or pressure on the place where I have bone pain X X
BP3/BP21 I have bone pain even when I sit oor lie4 still X X
BP4 I need help doing my usual activities because of bone pain X X
BP5 I am forced to rest during the day obecause of/due to4 bone pain X X
BP6 I have trouble walking because of bone pain X X
BP7 Bone pain interferes with my ability to care for myself (bathing, dressing, eating, etc.) X X
BP8 Bone pain interferes with my social activities X X
BP9/ BP18 Bone pain owakes me up at night / interferes with my sleep4 X X
BP10 I am frustrated by my bone pain X X
BP11 I feel depressed about my bone pain X X
BP12 I worry that my bone pain will get worse X X
BP13 My o family has trouble understanding when my4 bone pain interferes with my oactivity/family life4 X X
BP14 Bone pain interferes with my ability to do vigorous activity (exercise, heavy lifting, etc.) X
BP15 I have trouble concentrating due to my bone pain X
BP16 I have difﬁculty coping with my bone pain X
BP17 I have difﬁculty working due to my bone pain (including work at home) X
Q7 In how many places in your body have you felt bone pain? X X
Wording differences between versions are indicated byo 4 .
Table 2
Number of patients who completed FACT-BP and BPI at each time point on study.
Adapted from [11].
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now (p¼0.234). Correlations between the FACT-BP and BPI scores
were moderate to strong. Speciﬁcally, at baseline in the combined
sample, the Pearson correlation coefﬁcient between the FACT-BP
with BPI worst pain was 0.70, with BPI average pain was 0.45,
and with BPI pain right now was 0.57.
3.2. Correlation between pain scores and bone turnover markers
Pearson's correlation coefﬁcients and associated p-values are
shown in Table 3. Signiﬁcant correlations were observed between
levels of CTx and pain scores as assessed by FACT-BP (r¼0.487 and
p¼0.006) or BPI (r¼0.491 and p¼0.006) at baseline, however no
signiﬁcant correlations were observed with similar measures taken
at week 12 on study. BSAP at baseline was also signiﬁcantly
correlated with pain scores assessed by. FACT-BP (r¼0.363 and
p¼0.05), and trended with baseline pain scores as determined by
BPI (r¼0.329 and p¼0.08). No signiﬁcant correlations were observed
for BSAP with pain assessed by either tool at the 12 week time point
(all ro0.20).
4. Conclusion
Despite skeletal morbidity being associated with reduced
quality of life and shortened survival, a reduction in the rate of
skeletal related events (SREs) with bone-targeted agents has not
shown any improvement in global quality of life scores or survival
[8–12]. This raises a question regarding the sole use of SREs as
clinically relevant endpoints. Bone pain is usually the earliest and
most common symptom in patients developing skeletal metas-
tases. Patient-reported bone pain reﬂects an individual patient's
experience regarding pain severity and its impact on functioning
and QoL. Bone pain is a logical candidate for evaluating treatment
efﬁcacy. Several groups have therefore been developing scores that
are meaningful, valid, easy and fast to complete and assess.
Matza and colleagues measured bone pain in oncology trials,
and concluded that most approaches used simple assessment of
general bodily pain, often with single items [2]. They recom-
mended that bone pain assessment tools be validated within the
target population (i.e., people with bone pain), and have sufﬁcient
content validity to represent the important concerns and speciﬁc
impact of this unique pain experience. The Functional Assessment
of Cancer Therapy-Bone Pain (FACT-BP) was developed in 2004
and published in 2009 [5], to provide such a tool. Similarly, others
have tried to link biomarkers of bone turnover with a range of
other pertinent surrogates [13].
The objectives of this study were to evaluate the performance
of FACT-BP in comparison to the BPI assessment in the context of a
pilot randomized prospective trial comparing a de-escalating
bisphosphonate regimen (12 week) to the standard 3–4 weekly
regimen. BPI is a commonly used instrument for assessment of
bone pain and its interference with independent functioning and
quality of life in cancer patients in large clinical trials and in
routine clinical activity. While it is short and simple to use, it is less
speciﬁc with respect to its ability to assess the impact of pain on
patients' quality of life. The FACT-BP questionnaire is a relatively
brief alternative, though not as brief as BPI, but it covers a wider
range of relevant content. This includes more detailed and speciﬁc
characteristics of cancer-related bone pain, its impact on a
patient's ability to walk, perform regular daily activity, and ability
to work. The FACT-BP questionnaire also covers important patient
psycho-social aspects such as ability to cope with pain, inﬂuence
of bone pain on patients' anxiety level and their overall view of
their malignant condition, as well as the inﬂuence of their pain on
social activity and family life.
The current results show that FACT-BP and BPI correlated well
with each other over time. In addition, using either of these
methods of assessment of pain, no differences were observed
between the pain scores in the two study arms. While interest-
ingly, we acknowledge the limitations of the current study.
REFORM was a small randomized pilot study, thus it remains
possible that the small number of patients analyzed presently
could impact the present results. However, our ﬁndings support
the use of FACT-BP in larger cohorts assessing bone targeted trials,
particularly those focused on patients considered to be at low risk,
as levels of the standard bone turnover biomarkers CTx and BSAP
may not truly reﬂect the impact of the disease on a patient's well
being. Our reasoning for this choice is that it correlates quite well
with the most commonly-used pain instrument in prior bone pain
trials, the BPI, and yet it introduces a wider variety of content
which enhances the validity and applicability of the assessment to
patients' lives [2]. We thus plan to incorporate FACT-BP in larger
bone-targeted trials for further evaluation of its validity.
It is also of interest that while the biomarker of bone turnover
measured in this study, namely CTx, correlated with pain as
measured by both assessment tools at baseline, CTx levels did
not appear to correlate with pain scores when measured at
12 weeks on study. While the reasons for this remain unclear,
we speculate that the modest, but statistically insigniﬁcant rise in
CTx levels observed in patients in the de-escalated treatment arm
may contribute to the lack of correlation with pain scores at
12 weeks. Importantly, however, despite modest rises in CTx, pain
scores were not signiﬁcantly different in the two treatment arms
suggesting that de-escalation of bisphosphonate treatment in this
low risk group can still effectively control patient's pain.
In conclusion, the FACT-BP is a validated questionnaire asses-
sing patient reported issues around metastatic bone disease. In
order for us to improve the care of our patients we need reliable
yet pragmatic scores that can be used to drive practice changing
Fig. 1. FACT-BP scores over time in each treatment arm. Adapted from [11].
Q3-4¼pamidronate every 3–4 weeks; q12¼pamidronate every 12 weeks.
Table 3
Pearson's Correlation Coefﬁcients of Biomarkers with Pain Score Assessments.
Assessment tool Baseline Week 12
CTx BSAP CTx BSAP
FACT-BP 0.487 0.363 0.122 0.002
p¼0.006 p¼0.05 p¼0.59 p¼0.99
BPI 0.491 0.329 0.193 0.046
p¼0.006 p¼0.08 p¼0.39 p¼0.84
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research and also standard patient care in the real world, non-trial
setting. In addition, we need more studies evaluating the correla-
tion between subjective measures such as pain score and objective
biomarker measures so that smaller trials can be designed to
answer important clinical questions without the need for SREs to
be the primary study endpoint.
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